BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 25966772)

  • 61. Pazopanib in pretreated advanced neuroendocrine tumors: a phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE).
    Grande E; Capdevila J; Castellano D; Teulé A; Durán I; Fuster J; Sevilla I; Escudero P; Sastre J; García-Donas J; Casanovas O; Earl J; Ortega L; Apellaniz-Ruiz M; Rodriguez-Antona C; Alonso-Gordoa T; Díez JJ; Carrato A; García-Carbonero R
    Ann Oncol; 2015 Sep; 26(9):1987-1993. PubMed ID: 26063633
    [TBL] [Abstract][Full Text] [Related]  

  • 62. The "next-generation" knowledge of papillary thyroid carcinoma.
    Costa V; Esposito R; Pallante P; Ciccodicola A; Fusco A
    Cell Cycle; 2015; 14(13):2018-21. PubMed ID: 26030480
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Metastatic medullary thyroid cancer: a dramatic response to a systemic chemotherapy (temozolomide and capecitabine) regimen.
    Lacin S; Esin E; Karakas Y; Yalcin S
    Onco Targets Ther; 2015; 8():1039-42. PubMed ID: 25999738
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Reactive C cell hyperplasia as an incidental finding after thyroidectomy for papillary carcinoma.
    Manatakis DK; Bakavos A; Soulou VN; Dimakis C; Tseleni-Balafouta S
    Hormones (Athens); 2019 Sep; 18(3):289-295. PubMed ID: 31292912
    [TBL] [Abstract][Full Text] [Related]  

  • 65. C-cell hyperplasia and medullary thyroid carcinoma in patients routinely screened for serum calcitonin.
    Kaserer K; Scheuba C; Neuhold N; Weinhäusel A; Vierhapper H; Haas OA; Niederle B
    Am J Surg Pathol; 1998 Jun; 22(6):722-8. PubMed ID: 9630179
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Medullary Thyroid Carcinoma in a Patient with MEN 1 Syndrome. Case Report and Literature Review.
    Friziero A; Da Dalt G; Piotto A; Serafini S; Grego A; Galuppini F; Pennelli G; Sperti C
    Onco Targets Ther; 2020; 13():7599-7603. PubMed ID: 32801775
    [TBL] [Abstract][Full Text] [Related]  

  • 67. [Non-neoplastic hypercalcitoninemia. Pathological anatomy].
    Saint-André JP; Guyétant S
    Ann Endocrinol (Paris); 1996; 57(1):23-6. PubMed ID: 8734285
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Histopathology of C Cells and Medullary Thyroid Carcinoma.
    Schmid KW
    Recent Results Cancer Res; 2015; 204():41-60. PubMed ID: 26494383
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Physiologic versus neoplastic C-cell hyperplasia of the thyroid: separation of distinct histologic and biologic entities.
    Perry A; Molberg K; Albores-Saavedra J
    Cancer; 1996 Feb; 77(4):750-6. PubMed ID: 8616768
    [TBL] [Abstract][Full Text] [Related]  

  • 70. ["Physiological" and "neoplastic" C-cell hyperplasia of the thyroid. Morphologically and biologically distinct entities?].
    Hinze R; Gimm O; Brauckhoff M; Schneyer U; Dralle H; Holzhausen HJ
    Pathologe; 2001 Jul; 22(4):259-65. PubMed ID: 11490939
    [TBL] [Abstract][Full Text] [Related]  

  • 71. C-cell hyperplasia and medullary thyroid carcinoma: clinicopathological and genetic correlations in 66 consecutive patients.
    Guyétant S; Josselin N; Savagner F; Rohmer V; Michalak S; Saint-André JP
    Mod Pathol; 2003 Aug; 16(8):756-63. PubMed ID: 12920219
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The influence of gender, age, and RET polymorphisms on C-cell hyperplasia and medullary thyroid carcinoma.
    Weinhaeusel A; Scheuba C; Lauss M; Kriegner A; Kaserer K; Vierlinger K; Haas OA; Niederle B
    Thyroid; 2008 Dec; 18(12):1269-76. PubMed ID: 18976163
    [TBL] [Abstract][Full Text] [Related]  

  • 73. C-cell hyperplasia and medullary thyroid carcinoma in the rat. An immunohistochemical and ultrastructural analysis.
    DeLellis RA; Nunnemacher G; Bitman WR; Gagel RF; Tashjian AH; Blount M; Wolfe HJ
    Lab Invest; 1979 Feb; 40(2):140-54. PubMed ID: 431034
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Incidental thyroid C cell hyperplasia: clinical significance and implications in practice.
    Sakorafas GH; Nasikas D; Thanos D; Gantzoulas S
    Oncol Res Treat; 2015; 38(5):249-52. PubMed ID: 25966772
    [TBL] [Abstract][Full Text] [Related]  

  • 75.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 76.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 77.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 78.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 79.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 80.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.